Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
Recruiting
1,000 enrolled
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
Completed
1,340 enrolled
Vaccine Therapy in Treating Patients With Multiple Myeloma
Phase 2 Completed
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
Completed
902 enrolled
BMT CTN 0102
Phase 3 Completed
710 enrolled 19 charts
Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)
Terminated
225 enrolled
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances
Phase 2 Completed
70 enrolled
Testing a Spanish Version of a Patient Toxicity Questionnaire
Completed
112 enrolled
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
Phase 2 Withdrawn
Experimental Bone Marrow Transplant Protocol
Phase 2 Completed
14 enrolled
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
Phase 2 Completed
50 enrolled 12 charts
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase 3 Completed
Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
Phase 2 Unknown
30 enrolled
Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer
Phase 3 Unknown
80 enrolled
Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma
Phase 1/2 Completed
56 enrolled
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
Phase 2 Unknown
10 enrolled
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Phase 2 Unknown
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
Phase 2 Unknown
52 enrolled
Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 3 Completed
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
Phase NA Unknown
35 enrolled
Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma
Phase 3 Unknown
750 enrolled
Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma
Phase 3 Unknown
1,000 enrolled
SU006668 in Treating Patients With Advanced Solid Tumors
Phase 1 Unknown
Beta Alethine in Treating Patients With Myeloma
Phase 1/2 Unknown
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
Phase 2 Unknown
30 enrolled
Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma
Phase 3 Unknown
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase 2 Unknown
35 enrolled
Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma
Phase 2 Completed
30 enrolled
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
Phase 2 Unknown
60 enrolled
Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase 2 Completed
35 enrolled
Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma
Phase 1/2 Completed
30 enrolled
Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma
Phase 3 Unknown
660 enrolled
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
Phase 2 Unknown
80 enrolled
Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Completed
36 enrolled
Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
Phase 3 Unknown
450 enrolled
Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure
Phase 3 Completed
280 enrolled
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma
Phase 2 Unknown
100 enrolled
High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy
Phase 3 Unknown
460 enrolled
Combination Chemotherapy in Treating Patients With Multiple Myeloma
Phase 2 Completed
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
Phase 2 Withdrawn
Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma
Phase 2 Completed
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
Phase 2 Completed
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
Phase 2 Completed
Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 2 Completed
Interleukin-12 in Treating Patients With Multiple Myeloma
Phase 2 Completed
40 enrolled
Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma
Phase 3 Completed
200 enrolled
Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer
Phase 3 Completed
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
Phase 1/2 Completed
30 enrolled
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
Phase 2 Completed
40 enrolled
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
Phase 1 Completed